" class="no-js "lang="en-US"> Carthera - Medtech Alert
Saturday, August 02, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

Carthera

About Carthera

Carthera

CarThera designs and develops innovative therapeutic ultrasound-based medical devices for treating brain disorders since 2010.

The company’s proprietary device called SonoCloud® is an intracranial ultrasound implant that temporarily opens the blood-brain barrier (BBB) and allows a significantly increased concentration of therapeutic molecules to reach the brain.

A Phase 1/2a clinical trial is underway in glioblastoma while the new treatment option could be suitable for a wide range of other indications, including Alzheimer’s disease.

Related Story

Diseases

 Carthera Receives FDA Breakthrough Device Designation for SonoCloud-9 System | Pharmtech Focus

Carthera Receives FDA Breakthrough Device Designation for SonoCloud-9 System

June 22 2022

Carthera, a French company that designs and develops SonoCloud, an innovative ultrasound-based medical device to […]

Diseases

 Carthera’s Sonocloud Technology Enhances the Efficacy of Immunotherapies for the Treatment of Brain Tumors | Pharmtech Focus

Carthera’s Sonocloud Technology Enhances the Efficacy of Immunotherapies for the Treatment of Brain Tumors

June 9 2021

CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain […]